Cystic Fibrosis with Chronic Pseudomonas Lung Infection (207) |
|
| Protocol Title | Cystic Fibrosis - Cystic Fibrosis with Chronic Pseudomonas Lung Infection (207) |
| Summary | MP-376 (also known as Aeroquin™), the investigational medication being tested in this research study, has an active ingredient of levofloxacin which is FDA-approved for those with lung infections.Participation in this trial will last 70 days. |
| Therapeutic Area | Cystic Fibrosis |
| Age Range | 12 years of age to no maximum age limit |
| Purpose | A physician near you is testing the safety and effectiveness of MP-376 (inhaled Levofloxacin) with placebo (an inactive or "dummy" medication) in a quick 4-6 minute, easy-to-use aerosol delivery. This study medication is designed to provide high concentrations of levofloxacin at the site of infection in the lung with less potential for resistance and side effects compared to other routes of administration. Qualified participants will receive study visits, study-realted laboratory work and study medication (MP-376) or placebo (dummy medication) at no cost and will be compensated for time and travel. |
| Who is Eligible? | To participate you must:
|
| Who is Not Eligible? | You are not eligible if you:
A study physician will discuss other exclusions with you. |
Click below to see if you qualify for this trial:
If already registered, login
If not a registered member, Register now for Free
Trial Locations per State
| Location | State | Address |
Trial Materials and Media
Printed Material
![]() |
| If you prefer to speak with a live operator please call our toll-free line @ 1-877-997-8839 |
| Click to enlarge |
![]() |
| If you prefer to speak with a live operator please call our toll-free line @ 1-877-997-8839 |
| Click to enlarge |

